Simplivia Healthcare
Closed-system Transfer Device for Safe Compounding and Administration
Company Overview
Snapshot
Founded in February 2019 by Oded Grinstein and David Delouya, Simplivia Healthcare operates with 51–200 employees. The company was acquired by FIMI Opportunity Funds in May 2019, integrating the Tevadaptor business unit from Teva Pharmaceutical Industries.
Business overview
Simplivia Healthcare develops and manufactures high-quality drug-delivery solutions designed to enhance the safety of healthcare professionals. The company's core products, Tevadaptor and Chemfort, utilize its patented Toxi-Guard system. This technology, integrated into vial adaptors, facilitates pressure equalization during use, preventing the escape of hazardous drug vapors and blocking airborne contaminants from entering drug vials during reconstitution and administration. Simplivia Healthcare serves the pharmaceutical and healthcare industries globally, focusing on drug delivery within the Health Tech & Life Sciences sector.
Strategic signal
In January 2021, Simplivia Healthcare acquired diagnostics company Novamed. This strategic acquisition signals Simplivia's intent to expand its product portfolio and market reach beyond its core drug-delivery solutions, indicating a move towards diversification within the broader healthcare technology landscape.
Log in to access full profile ›Company Intelligence Q&A
- When was Simplivia Healthcare founded?
- Simplivia Healthcare was founded in February 2019.
- Who are the founders of Simplivia Healthcare?
- Simplivia Healthcare was founded by Oded Grinstein and David Delouya.
- When was Simplivia Healthcare acquired?
- Simplivia Healthcare was acquired by FIMI Opportunity Funds in May 2019.
- What products does Simplivia Healthcare offer?
- Simplivia Healthcare offers products such as Chemfort, Toxi-Guard, and Tevadaptor, which are designed for safe drug compounding and administration.